Feedback / Questions
cagrilintide/semaglutide (CagriSema) - Novo Nordisk
CagriSema: "CagriSema demonstrated 22.7% weight loss in REDEFINE 1"; Obesity
(Novo Nordisk)
-
Feb 6, 2025 -
Q4 & FY2024 Results
P3 data
•
Obesity
https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf
Feb 6, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious